Diabetic Neuropathy Clinical Trial
Official title:
Cognitive Behavioral Therapy for Painful Diabetic Neuropathy
The primary objective of this study is to evaluate the usefulness of cognitive behavioral therapy (CBT) for the management of painful diabetic neuropathy. Participants will be randomly assigned to one of two treatment conditions: CBT plus standard medical care or standard medical care alone. CBT will be offered in ten, ninety-minute group sessions and will be provided by a psychologist with experience in the management of both diabetes and chronic pain. CBT will involve teaching and encouraging practice of adaptive pain coping skills such as relaxation skills, activity pacing, and positive self-statements, among others. This study will allow us to determine which treatment is superior in terms of improvements in pain management, functioning and overall quality of life.
Research Design: A randomized mixed factorial controlled design will be employed in which
CBT plus standard pharmaceutical care (CBT/SC) is compared to a standard pharmaceutical care
(SC) treatment condition. Participants will be randomized in equal numbers to the two
conditions. Repeated assessments of key outcome domains will occur at pretreatment/baseline
and at 12, 24 and 36 weeks following baseline.
Methodology: Study participants will be evaluated pre-treatment (baseline), 12 weeks
post-baseline (post-treatment) and at 24 and 36 weeks post-baseline (follow-up). Baseline
assessment will include a neurological examination with a nerve conduction study to confirm
the diagnosis of diabetic neuropathy. The primary outcome measure will be pain intensity.
Secondary outcome measures will be pain quality, pain-related disability, physical and
emotional functioning. Measures of treatment feasibility will also be examined. Participants
receiving CBT will attend 10 weekly, group treatment sessions of 90 minutes. A target sample
size of approximately 120 participants will be recruited.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04025320 -
The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy
|
N/A | |
Completed |
NCT02659007 -
Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga
|
Phase 1 | |
Completed |
NCT01953757 -
A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)
|
N/A | |
Completed |
NCT01707979 -
NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes
|
N/A | |
Completed |
NCT00608439 -
Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00576277 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT00235443 -
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00931879 -
Lovaza® and Microvascular Function in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00101426 -
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
|
Phase 3 | |
Completed |
NCT00190970 -
The Effect of Ruboxistaurin on Small Fiber Function
|
Phase 2 | |
Completed |
NCT00238550 -
Study of CBME in the Relief of Painful Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT05573685 -
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training
|
N/A | |
Recruiting |
NCT02341261 -
Activity for Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01822925 -
Study of DA-9801 to Treat Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT01690962 -
A Nutritional Intervention for Diabetic Neuropathy
|
N/A | |
Terminated |
NCT00993018 -
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
|
Phase 2 | |
Withdrawn |
NCT02315235 -
The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy
|
N/A | |
Completed |
NCT00496457 -
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT02606747 -
The Balance Control Mechanism of DPN Patients
|
N/A | |
Completed |
NCT02068027 -
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
|
Phase 2 |